JP2011510913A5

JP2011510913A5 -

Download PDF

Info

Publication number: JP2011510913A5
Authority: JP; Japan
Prior art keywords: antibody; seq; variable region; chain variable; antigen
Prior art date: 2008-12-29
Legal status : Granted

Application number

JP2010540936A

Other languages

English (en)

Japanese (ja)

Other versions

JP5730020B2 (ja

JP2011510913A (ja

Filing date

2008-12-29

Publication date

2012-04-12

2008-12-29 Application filed filed Critical

2008-12-29 Priority claimed from PCT/US2008/088493 external-priority patent/WO2009086539A2/en

2011-04-07 Publication of JP2011510913A publication Critical patent/JP2011510913A/ja

2012-04-12 Publication of JP2011510913A5 publication Critical patent/JP2011510913A5/ja

2015-06-03 Application granted granted Critical

2015-06-03 Publication of JP5730020B2 publication Critical patent/JP5730020B2/ja

Status Active legal-status Critical Current

2028-12-29 Anticipated expiration legal-status Critical

Links

239000012634 fragment Substances 0.000 claims description 343
230000027455 binding Effects 0.000 claims description 265
108090000765 processed proteins & peptides Proteins 0.000 claims description 254
239000000427 antigen Substances 0.000 claims description 246
108091007433 antigens Proteins 0.000 claims description 245
102000036639 antigens Human genes 0.000 claims description 245
238000000034 method Methods 0.000 claims description 179
125000003275 alpha amino acid group Chemical group 0.000 claims description 156
102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 117
108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 117
102000004196 processed proteins & peptides Human genes 0.000 claims description 117
208000023769 AA amyloidosis Diseases 0.000 claims description 81
108060003951 Immunoglobulin Proteins 0.000 claims description 80
102000018358 immunoglobulin Human genes 0.000 claims description 80
102000054727 Serum Amyloid A Human genes 0.000 claims description 78
206010002022 amyloidosis Diseases 0.000 claims description 76
108700028909 Serum Amyloid A Proteins 0.000 claims description 70
210000004027 cell Anatomy 0.000 claims description 70
239000003795 chemical substances by application Substances 0.000 claims description 68
239000000203 mixture Substances 0.000 claims description 67
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 56
229920001184 polypeptide Polymers 0.000 claims description 55
229910052731 fluorine Inorganic materials 0.000 claims description 52
208000037259 Amyloid Plaque Diseases 0.000 claims description 46
230000028993 immune response Effects 0.000 claims description 44
238000011282 treatment Methods 0.000 claims description 43
239000008194 pharmaceutical composition Substances 0.000 claims description 37
108020004707 nucleic acids Proteins 0.000 claims description 34
102000039446 nucleic acids Human genes 0.000 claims description 34
150000007523 nucleic acids Chemical class 0.000 claims description 34
229910052740 iodine Inorganic materials 0.000 claims description 31
239000002243 precursor Substances 0.000 claims description 31
208000023761 AL amyloidosis Diseases 0.000 claims description 30
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 30
108010071690 Prealbumin Proteins 0.000 claims description 29
230000001225 therapeutic effect Effects 0.000 claims description 28
102000009190 Transthyretin Human genes 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 25
101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 23
102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 23
229910052722 tritium Inorganic materials 0.000 claims description 22
102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 21
108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 21
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 20
229910052698 phosphorus Inorganic materials 0.000 claims description 20
229910052720 vanadium Inorganic materials 0.000 claims description 20
230000002265 prevention Effects 0.000 claims description 17
229910052727 yttrium Inorganic materials 0.000 claims description 17
101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 16
101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 16
101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 16
101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 16
101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 16
101710190759 Serum amyloid A protein Proteins 0.000 claims description 14
229910052700 potassium Inorganic materials 0.000 claims description 14
210000004602 germ cell Anatomy 0.000 claims description 13
210000004408 hybridoma Anatomy 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
238000011321 prophylaxis Methods 0.000 claims description 7
230000002285 radioactive effect Effects 0.000 claims description 7
241000192128 Gammaproteobacteria Species 0.000 claims description 6
230000002776 aggregation Effects 0.000 claims description 6
238000004220 aggregation Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 5
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 5
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
210000004962 mammalian cell Anatomy 0.000 claims description 4
229940126619 mouse monoclonal antibody Drugs 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 2
230000002194 synthesizing effect Effects 0.000 claims 1
102400000269 Amyloid protein A Human genes 0.000 description 219
101710144835 Amyloid protein A Proteins 0.000 description 216
108010029485 Protein Isoforms Proteins 0.000 description 74
102000001708 Protein Isoforms Human genes 0.000 description 74
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 74
230000002163 immunogen Effects 0.000 description 71
239000002671 adjuvant Substances 0.000 description 68
108090000623 proteins and genes Proteins 0.000 description 68
235000001014 amino acid Nutrition 0.000 description 66
235000018102 proteins Nutrition 0.000 description 63
102000004169 proteins and genes Human genes 0.000 description 63
229940024606 amino acid Drugs 0.000 description 60
201000010099 disease Diseases 0.000 description 60
150000001413 amino acids Chemical class 0.000 description 58
230000000875 corresponding effect Effects 0.000 description 46
241000699666 Mus <mouse, genus> Species 0.000 description 44
239000003814 drug Substances 0.000 description 43
206010028980 Neoplasm Diseases 0.000 description 34
201000011510 cancer Diseases 0.000 description 33
208000024891 symptom Diseases 0.000 description 30
210000001744 T-lymphocyte Anatomy 0.000 description 27
230000035772 mutation Effects 0.000 description 27
238000006467 substitution reaction Methods 0.000 description 27
210000001519 tissue Anatomy 0.000 description 24
230000000295 complement effect Effects 0.000 description 22
229940124597 therapeutic agent Drugs 0.000 description 22
206010035226 Plasma cell myeloma Diseases 0.000 description 21
229940079593 drug Drugs 0.000 description 20
238000002864 sequence alignment Methods 0.000 description 20
108010070163 amyloid protein AL Proteins 0.000 description 19
210000004072 lung Anatomy 0.000 description 19
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 17
210000003719 b-lymphocyte Anatomy 0.000 description 17
208000015181 infectious disease Diseases 0.000 description 17
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 17
239000002773 nucleotide Substances 0.000 description 17
125000003729 nucleotide group Chemical group 0.000 description 17
208000024827 Alzheimer disease Diseases 0.000 description 16
208000008839 Kidney Neoplasms Diseases 0.000 description 16
206010003246 arthritis Diseases 0.000 description 16
150000001875 compounds Chemical class 0.000 description 16
230000008021 deposition Effects 0.000 description 16
230000000069 prophylactic effect Effects 0.000 description 16
229910052717 sulfur Inorganic materials 0.000 description 16
238000012360 testing method Methods 0.000 description 16
210000001035 gastrointestinal tract Anatomy 0.000 description 15
210000000056 organ Anatomy 0.000 description 15
208000002574 reactive arthritis Diseases 0.000 description 15
230000004044 response Effects 0.000 description 15
239000007790 solid phase Substances 0.000 description 15
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 14
102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 14
208000003456 Juvenile Arthritis Diseases 0.000 description 14
102100035846 Pigment epithelium-derived factor Human genes 0.000 description 14
201000004681 Psoriasis Diseases 0.000 description 14
208000033464 Reiter syndrome Diseases 0.000 description 14
206010038389 Renal cancer Diseases 0.000 description 14
230000001684 chronic effect Effects 0.000 description 14
201000010982 kidney cancer Diseases 0.000 description 14
108090000102 pigment epithelium-derived factor Proteins 0.000 description 14
206010039073 rheumatoid arthritis Diseases 0.000 description 14
206010002556 Ankylosing Spondylitis Diseases 0.000 description 13
208000027496 Behcet disease Diseases 0.000 description 13
208000009137 Behcet syndrome Diseases 0.000 description 13
206010024229 Leprosy Diseases 0.000 description 13
208000004210 Pressure Ulcer Diseases 0.000 description 13
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 13
201000009267 bronchiectasis Diseases 0.000 description 13
238000004422 calculation algorithm Methods 0.000 description 13
108020001507 fusion proteins Proteins 0.000 description 13
102000037865 fusion proteins Human genes 0.000 description 13
229940072221 immunoglobulins Drugs 0.000 description 13
210000001503 joint Anatomy 0.000 description 13
201000000050 myeloid neoplasm Diseases 0.000 description 13
230000009885 systemic effect Effects 0.000 description 13
102000001049 Amyloid Human genes 0.000 description 12
108010094108 Amyloid Proteins 0.000 description 12
208000005024 Castleman disease Diseases 0.000 description 12
208000011231 Crohn disease Diseases 0.000 description 12
206010016207 Familial Mediterranean fever Diseases 0.000 description 12
101000869480 Homo sapiens Serum amyloid A-1 protein Proteins 0.000 description 12
206010031252 Osteomyelitis Diseases 0.000 description 12
208000027207 Whipple disease Diseases 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
238000003556 assay Methods 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
201000009277 hairy cell leukemia Diseases 0.000 description 12
230000003053 immunization Effects 0.000 description 12
208000027866 inflammatory disease Diseases 0.000 description 12
230000009870 specific binding Effects 0.000 description 12
201000008827 tuberculosis Diseases 0.000 description 12
206010004146 Basal cell carcinoma Diseases 0.000 description 11
208000017604 Hodgkin disease Diseases 0.000 description 11
208000021519 Hodgkin lymphoma Diseases 0.000 description 11
208000010747 Hodgkins lymphoma Diseases 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
241000894006 Bacteria Species 0.000 description 10
206010061218 Inflammation Diseases 0.000 description 10
208000036824 Psoriatic arthropathy Diseases 0.000 description 10
206010037660 Pyrexia Diseases 0.000 description 10
229940037003 alum Drugs 0.000 description 10
238000002649 immunization Methods 0.000 description 10
230000004054 inflammatory process Effects 0.000 description 10
230000006337 proteolytic cleavage Effects 0.000 description 10
241000894007 species Species 0.000 description 10
108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
206010037601 Pyelonephritis chronic Diseases 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
201000006368 chronic pyelonephritis Diseases 0.000 description 9
230000001939 inductive effect Effects 0.000 description 9
230000001575 pathological effect Effects 0.000 description 9
210000003491 skin Anatomy 0.000 description 9
239000013598 vector Substances 0.000 description 9
102100034452 Alternative prion protein Human genes 0.000 description 8
108020004414 DNA Proteins 0.000 description 8
241000282412 Homo Species 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
230000002159 abnormal effect Effects 0.000 description 8
230000036755 cellular response Effects 0.000 description 8
208000037976 chronic inflammation Diseases 0.000 description 8
208000037893 chronic inflammatory disorder Diseases 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
-1 fibrogen alpha chain Proteins 0.000 description 8
230000006870 function Effects 0.000 description 8
102000057429 human SAA1 Human genes 0.000 description 8
210000003734 kidney Anatomy 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
238000003127 radioimmunoassay Methods 0.000 description 8
230000007017 scission Effects 0.000 description 8
101100512220 Arabidopsis thaliana MAA3 gene Proteins 0.000 description 7
101100086314 Chlamydomonas reinhardtii RAA2 gene Proteins 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
108091000054 Prion Proteins 0.000 description 7
230000005867 T cell response Effects 0.000 description 7
230000037396 body weight Effects 0.000 description 7
238000001514 detection method Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
208000022256 primary systemic amyloidosis Diseases 0.000 description 7
238000012216 screening Methods 0.000 description 7
208000015052 syndromic microphthalmia 2 Diseases 0.000 description 7
206010011985 Decubitus ulcer Diseases 0.000 description 6
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
230000003942 amyloidogenic effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
239000012636 effector Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000004927 fusion Effects 0.000 description 6
230000003308 immunostimulating effect Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
238000002372 labelling Methods 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
238000002823 phage display Methods 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000009261 transgenic effect Effects 0.000 description 6
239000013603 viral vector Substances 0.000 description 6
230000004580 weight loss Effects 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 5
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 5
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
102000015779 HDL Lipoproteins Human genes 0.000 description 5
108010010234 HDL Lipoproteins Proteins 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
208000030289 Lymphoproliferative disease Diseases 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
101100476588 Mus musculus Saa1 gene Proteins 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
206010033128 Ovarian cancer Diseases 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
102100029290 Transthyretin Human genes 0.000 description 5
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
210000002216 heart Anatomy 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
201000000564 macroglobulinemia Diseases 0.000 description 5
230000000813 microbial effect Effects 0.000 description 5
239000002245 particle Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
208000016261 weight loss Diseases 0.000 description 5
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical group OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 4
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 4
208000003808 Amyloid Neuropathies Diseases 0.000 description 4
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
101001093100 Drosophila melanogaster Scaffold protein salvador Proteins 0.000 description 4
206010053776 Eosinophilic cellulitis Diseases 0.000 description 4
102000009109 Fc receptors Human genes 0.000 description 4
108010087819 Fc receptors Proteins 0.000 description 4
102000006395 Globulins Human genes 0.000 description 4
108010044091 Globulins Proteins 0.000 description 4
101000637835 Homo sapiens Serum amyloid A-4 protein Proteins 0.000 description 4
101000772194 Homo sapiens Transthyretin Proteins 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 4
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
206010060880 Monoclonal gammopathy Diseases 0.000 description 4
206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
206010061535 Ovarian neoplasm Diseases 0.000 description 4
102100032277 Serum amyloid A-1 protein Human genes 0.000 description 4
101710083332 Serum amyloid A-2 protein Proteins 0.000 description 4
102100032007 Serum amyloid A-2 protein Human genes 0.000 description 4
208000005718 Stomach Neoplasms Diseases 0.000 description 4
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 4
208000008526 Wells syndrome Diseases 0.000 description 4
230000002917 arthritic effect Effects 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
201000010881 cervical cancer Diseases 0.000 description 4
230000008859 change Effects 0.000 description 4
208000010877 cognitive disease Diseases 0.000 description 4
238000012875 competitive assay Methods 0.000 description 4
238000013170 computed tomography imaging Methods 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
229960001438 immunostimulant agent Drugs 0.000 description 4
239000003022 immunostimulating agent Substances 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000027939 micturition Effects 0.000 description 4
208000027061 mild cognitive impairment Diseases 0.000 description 4
208000033808 peripheral neuropathy Diseases 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000002603 single-photon emission computed tomography Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
201000011549 stomach cancer Diseases 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
102000007592 Apolipoproteins Human genes 0.000 description 3
108010071619 Apolipoproteins Proteins 0.000 description 3
108010039939 Cell Wall Skeleton Proteins 0.000 description 3
206010008342 Cervix carcinoma Diseases 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
208000001333 Colorectal Neoplasms Diseases 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
108010061642 Cystatin C Proteins 0.000 description 3
102000012192 Cystatin C Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 3
108090001064 Gelsolin Proteins 0.000 description 3
102000004878 Gelsolin Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 3
101000637821 Homo sapiens Serum amyloid A-2 protein Proteins 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108010039918 Polylysine Proteins 0.000 description 3
102000029797 Prion Human genes 0.000 description 3
206010037596 Pyelonephritis Diseases 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
206010046788 Uterine haemorrhage Diseases 0.000 description 3
206010046910 Vaginal haemorrhage Diseases 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
230000004596 appetite loss Effects 0.000 description 3
230000001588 bifunctional effect Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000004520 cell wall skeleton Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
208000019069 chronic childhood arthritis Diseases 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000006806 disease prevention Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
201000006061 fatal familial insomnia Diseases 0.000 description 3
206010016256 fatigue Diseases 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000001631 haemodialysis Methods 0.000 description 3
208000006750 hematuria Diseases 0.000 description 3
230000000322 hemodialysis Effects 0.000 description 3
102000050695 human SAA2 Human genes 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000009851 immunogenic response Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000007917 intracranial administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
208000019017 loss of appetite Diseases 0.000 description 3
235000021266 loss of appetite Nutrition 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000178 monomer Substances 0.000 description 3
230000002981 neuropathic effect Effects 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
210000001539 phagocyte Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920000656 polylysine Polymers 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000002797 proteolythic effect Effects 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
150000007949 saponins Chemical class 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
229960000814 tetanus toxoid Drugs 0.000 description 3
201000007905 transthyretin amyloidosis Diseases 0.000 description 3
229910052721 tungsten Inorganic materials 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 2
HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 2
101710180042 39kDa core protein Proteins 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000710929 Alphavirus Species 0.000 description 2
206010059047 Amyloidoma Diseases 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 2
108010059886 Apolipoprotein A-I Proteins 0.000 description 2
241000272478 Aquila Species 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
102000001327 Chemokine CCL5 Human genes 0.000 description 2
108010055166 Chemokine CCL5 Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
241000759568 Corixa Species 0.000 description 2
101710200291 Cyclin-dependent kinase 5 activator 2 Proteins 0.000 description 2
101710113614 DNA primase small subunit PriS Proteins 0.000 description 2
208000019505 Deglutition disease Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010016202 Familial Amyloidosis Diseases 0.000 description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
206010018180 Genital ulceration Diseases 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 2
101000679575 Homo sapiens Trafficking protein particle complex subunit 2 Proteins 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100021794 Microtubule-associated protein 4 Human genes 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
101100041603 Mus musculus Saa2 gene Proteins 0.000 description 2
101100041608 Mus musculus Saa3 gene Proteins 0.000 description 2
101100041612 Mus musculus Saa4 gene Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
108091061960 Naked DNA Proteins 0.000 description 2
206010031256 Osteomyelitis chronic Diseases 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
241000223960 Plasmodium falciparum Species 0.000 description 2
206010036673 Primary amyloidosis Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
101150026634 SAA3 gene Proteins 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
102100032016 Serum amyloid A-4 protein Human genes 0.000 description 2
241000607768 Shigella Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000019355 Synuclein Human genes 0.000 description 2
108050006783 Synuclein Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102100022613 Trafficking protein particle complex subunit 2 Human genes 0.000 description 2
102100023132 Transcription factor Jun Human genes 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 2
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
LHSHCLPXMPQXCS-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-nitrooxypropyl] nitrate Chemical compound [O-][N+](=O)OCC(CO)(CO)CO[N+]([O-])=O LHSHCLPXMPQXCS-UHFFFAOYSA-N 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000001746 atrial effect Effects 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
238000004820 blood count Methods 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
229960004630 chlorambucil Drugs 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000006957 competitive inhibition Effects 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
PQYUGUXEJHLOIL-UHFFFAOYSA-N diethoxysilyl triethyl silicate Chemical compound C(C)O[SiH](O[Si](OCC)(OCC)OCC)OCC PQYUGUXEJHLOIL-UHFFFAOYSA-N 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
210000004696 endometrium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
208000017105 hereditary amyloidosis Diseases 0.000 description 2
108700019570 human SAA3P Proteins 0.000 description 2
102000046925 human SAA3P Human genes 0.000 description 2
102000047310 human SAA4 Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
239000002596 immunotoxin Substances 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
210000003632 microfilament Anatomy 0.000 description 2
210000000274 microglia Anatomy 0.000 description 2
230000002025 microglial effect Effects 0.000 description 2
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
229960005225 mifamurtide Drugs 0.000 description 2
229940035032 monophosphoryl lipid a Drugs 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000007764 o/w emulsion Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000005457 optimization Methods 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000002688 persistence Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
239000001044 red dye Substances 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
210000004761 scalp Anatomy 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
206010040882 skin lesion Diseases 0.000 description 2
231100000444 skin lesion Toxicity 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
238000011820 transgenic animal model Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
GYTROFMCUJZKNA-UHFFFAOYSA-N triethyl triethoxysilyl silicate Chemical compound CCO[Si](OCC)(OCC)O[Si](OCC)(OCC)OCC GYTROFMCUJZKNA-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
210000000626 ureter Anatomy 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
208000027121 wild type ATTR amyloidosis Diseases 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
PEZMQPADLFXCJJ-ZETCQYMHSA-N 2-[[2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(O)=O PEZMQPADLFXCJJ-ZETCQYMHSA-N 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
229940117976 5-hydroxylysine Drugs 0.000 description 1
WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
208000026326 Adult-onset Still disease Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100026882 Alpha-synuclein Human genes 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
101800001479 Amyloid protein A Proteins 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010068975 Bone atrophy Diseases 0.000 description 1
108700012434 CCL3 Proteins 0.000 description 1
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
101710163595 Chaperone protein DnaK Proteins 0.000 description 1
102000000013 Chemokine CCL3 Human genes 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000019736 Cranial nerve disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101710158332 Diuretic hormone Proteins 0.000 description 1
101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101100425960 Escherichia coli traT gene Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000002476 Falciparum Malaria Diseases 0.000 description 1
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
101710163305 Fibril protein Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
101710113864 Heat shock protein 90 Proteins 0.000 description 1
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
101710165610 Heat-stable 19 kDa antigen Proteins 0.000 description 1
208000000616 Hemoptysis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 1
101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 1
101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 1
206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010073807 IgG Receptors Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100020881 Interleukin-1 alpha Human genes 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
102000003812 Interleukin-15 Human genes 0.000 description 1
108090000172 Interleukin-15 Proteins 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
206010022653 Intestinal haemorrhages Diseases 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
101710164702 Major outer membrane protein Proteins 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001092142 Molina Species 0.000 description 1
208000011948 Multi-organ disease Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
241000186362 Mycobacterium leprae Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
108010049175 N-substituted Glycines Proteins 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
101000801721 Schistosoma mansoni Triosephosphate isomerase Proteins 0.000 description 1
206010039811 Secondary amyloidosis Diseases 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
102100036202 Serum amyloid P-component Human genes 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010040840 Skin erosion Diseases 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
101150084279 TM gene Proteins 0.000 description 1
GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
102100028748 Transportin-1 Human genes 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 1
108090000185 alpha-Synuclein Proteins 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003941 amyloidogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
102000025171 antigen binding proteins Human genes 0.000 description 1
108091000831 antigen binding proteins Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037182 bone density Effects 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
229960003150 bupivacaine Drugs 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
208000020670 canker sore Diseases 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
210000003109 clavicle Anatomy 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
206010011005 corneal dystrophy Diseases 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
208000014826 cranial nerve neuropathy Diseases 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
AFZSMODLJJCVPP-UHFFFAOYSA-N dibenzothiazol-2-yl disulfide Chemical compound C1=CC=C2SC(SSC=3SC4=CC=CC=C4N=3)=NC2=C1 AFZSMODLJJCVPP-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000003500 gene array Methods 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
208000021760 high fever Diseases 0.000 description 1
108010040030 histidinoalanine Proteins 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000005304 joining Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000244 kidney pelvis Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
208000030175 lameness Diseases 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002794 lymphocyte assay Methods 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
230000036244 malformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
230000009245 menopause Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000009854 mucosal lesion Effects 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
210000000282 nail Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
235000015816 nutrient absorption Nutrition 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940067631 phospholipid Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
208000028280 polygenic inheritance Diseases 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
231100000857 poor renal function Toxicity 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
208000026526 progressive weakness Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000455 protein structure prediction Methods 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
210000003131 sacroiliac joint Anatomy 0.000 description 1
230000037390 scarring Effects 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
230000035807 sensation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
210000001587 telencephalon Anatomy 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

JP2010540936A 2007-12-28 2008-12-29 アミロイドーシスの処置および予防 Active JP5730020B2 (ja)